Efficacy of peginterferon plus ribavirin for HIV-HCV co-infection. Results of Apricot study;Efficacité de l'interféron pégylé associé à la ribavirine en cas de co-infection VIH-VHC. Résultats de l'essai Apricot

Presse Medicale

Volumn 34, Issue 20 II, 2005, Pages 1589-1591

  Pialoux, G ^a  

^a HÔPITAL TENON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A; PLACEBO; RECOMBINANT ALPHA2A INTERFERON; RIBAVIRIN;

CHRONIC HEPATITIS; CLINICAL TRIAL; DRUG EFFICACY; GENOTYPE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRACTICE GUIDELINE; PREDICTION; RANDOMIZATION; REVIEW; SUPERINFECTION; TREATMENT INDICATION; TREATMENT RESPONSE; VALIDATION PROCESS; VIRUS LOAD;

EID: 29444434153     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0755-4982(05)84230-7     Document Type: Short Survey

References (4)

1. Torriani FJ, Rodriguez-Torres M, Rockstroh JK et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351: 438-50.
2. Carrat F, Bani-Sadr F, Pol S et al. Pegylated interferon α-2b vs tandard interferon α-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004; 292: 2839-48.
3. Chung RT, Andersen J, Volberding P et al. Peginterferon α-2a plus ribavirin versus interferon α-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004; 351; 451-9.
4. Mauss S, Valenti W, DePamphilis J et al. Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy. AIDS 2004; 18: F21-5.